Antigen sparing is a crucial tool in the development of vaccines, used to decrease the cost while speeding up the production of vaccines. By using a smaller antigen dose, adverse reactions are reduced at the site of the injection without impacting the immune response.

iosBio’s patented technology creates a stable form of a vaccine that is designed to be significantly more immunogenic. In some studies, iosBio has demonstrated an antigen sparing effect of up to 100-fold, in which one-hundredth of the usual vaccine dose gives an equivalent immune response.

iosBio’s OraPro-Flu™ provides an opportunity for multi-strain influenza vaccination in a single dose

iosBio’s OraPro-Flu™ uses antigen sparing to reduce the amount of each viral strain required within a vaccine, thereby creating ‘room’ for additional strains to be included in the same vaccine dose. iosBio’s antigen sparing technology has the potential application for other vaccine candidates, in-house or partnered.


  • Reduced local site reaction
  • Pandemic management: antigen sparing is regarded as a crucial tool for managing pandemic vaccine development, where worldwide vaccine production is limited or at the start of a pandemic when global production is not fully mobilised
  • Low cost per dose: antigen sparing allows more doses from a vaccine stock reducing the cost per dose
  • Increased supply: dose-sparing could ‘stretch’ the availability of vaccines where supply is limited by manufacturing capacity

Demonstration of antigen sparing using Influenza vaccine